The U.S. President Barack Obama has announced, in his State of the Union address on January 20, 2015, the Precision Medicine Initiative, a US$215-million program. For global precision medicine to become a reality, however, biological and environmental “variome” in previously understudied populations ought to be mapped and catalogued. Chief among the molecular targets that warrant global mapping is the organic anion-transporting polypeptide 1B1 (OATP1B1), encoded by solute carrier organic anion transporter family member 1B1 (SLCO1B1), a hepatic uptake transporter predominantly expressed in the basolateral side of hepatocytes. Human OATP1B1 plays a crucial role in the transport of a wide variety of substrates. This includes endogenous compounds such as bile salts as well as medicines, including benzylpenicillin, methotrexate, pravastatin, and rifampicin, and natural toxins microcystin and phalloidin. Genetic variations observed in the SLCO1B1 gene have been associated with altered in vitro and in vivo OATP1B1 transport activity, and consequently influencing patients' response to medicines, toxins, and susceptibility to common complex diseases. Well-characterized haplotypes, *5 (RS4149056C) and *15 (RS4149056T), have been associated with a strikingly reduced uptake of multiple OATP1B1 substrates, including estrone-3-sulfate, estradiol-17β-d-glucuronide, atorvastatin, cerivastatin, pravastatin, and rifampicin. In particular, RS4149056C is observed in 60% of the Cape admixed (CA) population and is associated with increased plasma concentrations of many statins as well as fexofenadine and repaglinide. We designed and optimized a SNaPshot minisequencing panel to characterize the variants of relevance for precision medicine in the clinic. We report here the first study on allele and genotype frequencies for 10 nonsynonymous, 4 synonymous, and 6 intronic single-nucleotide polymorphisms of SLCO1B1 in the Zulu and CA populations of South Africa. These variants are further contextualized here, in relation to their potential clinical relevance. These observations collectively contribute to current efforts to advance global precision medicine in understudied populations and resource-limited regions of the world.
Get full access to this article
View all access options for this article.
References
1.
AklilluE, MugusiS, NgaimisiE, et al. (2011). Frequency of the SLCO1B1 388a>g and the 521t>c polymorphism in Tanzania genotyped by a new lightcycler(r)-based method. Eur J Clin Pharmacol, 67, 1139–1145.
2.
AviviI, ZuckermanT, KriveyN, et al. (2014). Genetic polymorphisms predicting methotrexate blood levels and toxicity in adult non-Hodgkin lymphoma. Leuk Lymphoma, 55, 565–570.
3.
BirchK, DoveES, ChiappettaM, and GursoyUK. (2016). Biobanks in oral health: Promises and implications of post-neoliberal science and innovation. OMICS, 20, 36–41.
4.
CarrDF, O'MearaH, JorgensenAL, et al. (2013). SLCO1B1 genetic variant associated with statin-induced myopathy: A proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther, 94, 695–701.
5.
ChigutsaE, VisserME, SwartEC, et al. (2011). The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications. Antimicrob Agents Chemother, 55, 4122–4127.
6.
CouvertP, GiralP, DejagerS, et al. (2008). Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics, 9, 1217–1227.
7.
CvetkovicM, LeakeB, FrommMF, WilkinsonGR, and KimRB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos, 27, 866–871.
8.
DanikJS, ChasmanDI, MacfadyenJG, NybergF, BarrattBJ, and RidkerPM. (2013). Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J, 165, 1008–1014.
9.
DrysdaleCM, McgrawDW, StackCB, et al. (2000). Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA, 97, 6.
10.
D'SilvaS, ColahRB, GhoshK, and MukherjeeMB. (2014). Combined effects of the UGT1A1 and OATP2 gene polymorphisms as major risk factor for unconjugated hyperbilirubinemia in Indian neonates. Gene, 547, 18–22.
11.
EvansBJ, BurkeW, and JarvikGP. (2015). The FDA and genomic tests—Getting regulation right. N Engl J Med, 372, 2258–2264.
12.
Francesca NotarangeloM, MarzilianoN, Antonietta DemolaM, et al. (2012). Genetic predisposition to atorvastatin-induced myopathy: A case report. J Clin Pharm Ther, 37, 604–606.
13.
GengiahTN, BothaJH, SoowamberD, NaidooK, and Abdool KarimSS. (2014). Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries, 8, 987–993.
14.
GoricarK, KovacV, JazbecJ, ZakotnikB, LamovecJ, and DolzanV. (2014). Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics, 24, 514–521.
15.
GribbleMO, VorugantiVS, CroppCD, et al. (2013). SLCO1B1 variants and urine arsenic metabolites in the strong heart family study. Toxicol Sci, 136, 19–25.
16.
HagenbuchB, and MeierPJ. (2003). The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta, 1609, 1–18.
17.
HartkoornRC, KwanWS, ShallcrossV, et al. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics, 20, 112–120.
18.
HoosainN, NeneS, PearceB, JacobsC, Du PlessisM, and BenjeddouM. (2014). Genetic polymorphisms and haplotype structure of the organic cation transporter 1 gene in the Zulu population of South Africa. WASET Int J Biol Vet Agric Food Eng, 8, 7.
19.
HopewellJC, ParishS, OfferA, et al. (2013). Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the heart protection study. Eur Heart J, 34, 982–992.
20.
HuM, MakVW, and TomlinsonB. (2012). Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics, 22, 803–806.
21.
HubacekJA, DlouhaD, AdamkovaV, et al. (2015). SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit, 21, 1454–1459.
22.
IARC. (2004). Some drinking-water disinfectants and contaminants, including arsenic. IARC Monogr Eval Carcinog Risks Hum, 84, 269–477.
23.
JadaSR, XiaochenS, YanLY, et al. (2007). Pharmacogenetics of SLCO1B1: Haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J Clin Pharmacol, 63, 555–563.
24.
KalliokoskiA, NeuvonenPJ, and NiemiM. (2010). SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol, 107, 775–781.
25.
KameyamaY, YamashitaK, KobayashiK, HosokawaM, and ChibaK. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+c1007g, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics, 15, 513–522.
26.
KimRB. (2003). Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest, 33,(Suppl 2),1–5.
27.
KohlrauschFB, De Cassia EstrelaR, BarrosoPF, and Suarez-KurtzG. (2010). The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br J Clin Pharmacol, 69, 95–98.
28.
KoressaarT, and RemmM. (2007). Enhancements and modifications of primer design program primer3. Bioinformatics, 23, 1289–1291.
29.
LeabmanMK, HuangCC, DeyoungJ, et al. (2003). Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA, 100, 5896–5901.
30.
LeeE, SchumacherF, LewingerJP, et al. (2011). The association of polymorphisms in hormone metabolism pathway genes, menopausal hormone therapy, and breast cancer risk: A nested case-control study in the California teachers study cohort. Breast Cancer Res, 13, R37.
31.
LiJ, WangXR, ZhaiXW, et al. (2015). Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia. Int J Clin Exp Med, 8, 6109–6113.
32.
LiZ, ZhangZ, HeZ, et al. (2009). A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: Update of the SHEsis (http://analysis.bio-x.cn). Cell Res, 19, 519–523.
33.
Lopez-LopezE, Martin-GuerreroI, BallesterosJ, et al. (2011). Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer, 57, 612–619.
34.
LubomirovR, Di IulioJ, FayetA, et al. (2010). Adme pharmacogenetics: Investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics, 20, 217–230.
35.
MaullEA, AhsanH, EdwardsJ, et al. (2012). Evaluation of the association between arsenic and diabetes: A national toxicology program workshop review. Environ Health Perspect, 120, 13.
36.
MeloMS, BalancoL, BrancoCC, and Mota-VieiraL. (2015). Genetic variation in key genes associated with statin therapy in the azores islands (Portugal) healthy population. Ann Hum Biol, 42, 283–289.
37.
MoonK, GuallarE, and Navas-AcienA. (2012). Arsenic exposure and cardiovascular disease: An updated systematic review. Curr Atheroseler Rep, 14, 14.
38.
MourembouG, YasirM, AzharEI, et al. (2015). Rise of microbial culturomics: Noncontiguous finished genome sequence and description of Beduini massiliensis gen. nov., sp. nov. OMICS, 19, 766–776.
39.
MwinyiJ, KopkeK, SchaeferM, RootsI, and GerloffT. (2008). Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol, 64, 257–266.
40.
NiW, JiJ, DaiZ, et al. (2010). Flavopiridol pharmacogenetics: Clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One, 5, e13792.
41.
NiemiM, SchaeffelerE, LangT, et al. (2004). High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-c (OATP-C, SLCO1B1). Pharmacogenetics, 14, 429–440.
42.
NiesAT, NiemiM, BurkO, et al. (2013). Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med, 5, 1.
43.
OshiroC, MangraviteL, KleinT, and AltmanR. (2010). Pharmgkb very important pharmacogene: SLCO1B1. Pharmacogenet Genomics, 20, 6.
44.
PasanenMK, BackmanJT, NeuvonenPJ, and NiemiM. (2006). Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol, 62, 409–415.
45.
RadtkeS, ZolkO, RennerB, et al. (2013). Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood, 121, 5145–5153.
46.
RodriguesAC, PerinPM, PurimSG, et al. (2011). Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388a>g variant is determinant of increased atorvastatin response. Int J Mol Sci, 12, 5815–5827.
47.
RomaineSP, BaileyKM, HallAS, and BalmforthAJ. (2010). The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J, 10, 1–11.
48.
SEARCH Collaborative Group, LinkE, ParishS, et al. (2008). SLCO1B1 variants and statin-induced myopathy: A genomewide study. N Engl J Med, 359, 11.
49.
ShiYY, and HeL. (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res, 15, 97–98.
50.
ShitaraY, TakeuchiK, and HorieT. (2013). Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. J Pharm Sci, 102, 3427–3435.
51.
SinghH, and SittigDF. (2015). Advancing the science of measurement of diagnostic errors in healthcare: The safer DX framework. BMJ Qual Saf, 24, 103–110.
52.
SrivastavaA, SrivastavaA, SrivastavaN, ChoudhuriG, and MittalB. (2011). Organic anion transporter 1B1 (SLCO1B1) polymorphism and gallstone formation: High incidence of Exon4 CA genotype in female patients in North India. Hepatol Res, 41, 71–78.
53.
TironaRG, LeakeBF, MerinoG, and KimRB. (2001). Polymorphisms in OATP-C: Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem, 276, 35669–35675.
54.
TreiberA, SchneiterR, HauslerS, and StiegerB. (2007). Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin a, rifampicin, and sildenafil. Drug Metab Dispos, 35, 1400–1407.
55.
TrevinoLR, ShimasakiN, YangW, et al. (2009). Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol, 27, 5972–5978.
56.
TsamandourasN, DickinsonG, GuoY, et al. (2014). Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach. Clin Pharmacol Ther, 96, 90–100.
57.
UntergasserA, CutcutacheI, KoressaarT, et al. (2012). Primer3—New capabilities and interfaces. Nucleic Acids Res, 40, e115.
58.
VarenhorstC, ErikssonN, JohanssonÅ, et al. (2015). Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J, 36, 1901–1912.
59.
XiangX, HanY, NeuvonenM, et al. (2009). Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans. Pharmacogenet Genomics, 19, 447–457.
ZhangX, TierneyC, AlbrechtM, et al. (2013). Discordant associations between SLCO1B1 521T—>C and plasma levels of ritonavir-boosted protease inhibitors in aids clinical trials group study A5146. Ther Drug Monit, 35, 209–216.
62.
ZhangH, HeX, WangC, et al. (2014). Impact of SLCO1B1 521 T>C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate. Ped Blood & Can, 61, 2203–2207.
